Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transcription factor IIIB 50 kDa subunit (BRF2)
- Target
- BRF2
- Molecular classification
- Transcription factor, RNA polymerase III transcription factor complex subunit
01
Overview
Transcription factor IIIB 50 kDa subunit (BRF2) is a core component of the RNA polymerase III transcription initiation factor complex (TFIIIB), essential for the initiation of transcription of genes with upstream promoter elements, particularly small nuclear RNA genes. BRF2 is a TFIIB-like factor that is directly recruited to the TATA box by interacting with the TATA-binding protein, and is necessary for forming a stable pre-initiation complex for RNA polymerase III. Aberrations in BRF2 expression and function have been linked to the development and progression of various cancers, making it a potential biomarker and emerging therapeutic target, especially in oncology.
- Other names
- BRF2BRFUTFIIIB50RNA polymerase III transcription initiation factor 50 kDa subunitRNA polymerase III transcription initiation factor subunitBRF2 RNA polymerase III transcription initiation factor subunitb-related factor 2hTFIIIB50hBRFU
02
Mechanism of action
Not applicable for approved drugs. Investigational inhibitors would block the transcriptional activation function of BRF2, suppressing RNA polymerase III-dependent gene transcription and reducing tumor-associated gene expression
03
Biological functions
Transcription initiation for RNA polymerase III-dependent genes (notably small nuclear RNAs)Recruitment of RNA polymerase III to promoters with upstream elementsStabilization of transcription pre-initiation complexInteracts directly with the TATA-binding protein and TATA box in DNA
04
Disease associations
Cancer (overexpression has been implicated in several cancers, especially lung squamous cell carcinoma)Other (potentially related to general dysregulation of cell proliferation through transcriptional misregulation)
05
Safety considerations
Targeting transcription factors may have broad and systemic effects, potentially impacting normal cell transcription and viability.Specificity of intervention is a therapeutic challenge due to BRF2’s role in fundamental cellular processes
06
Interacting drugs
None directly approved or widely cited as of 2024; BRF2 is considered an emerging or exploratory oncology target and direct pharmacological inhibitors are under investigation in preclinical studies
07
Biomarkers
BRF2 overexpression itself is a proposed biomarker for certain cancers, such as lung squamous cell carcinoma and potentially other epithelial malignancies
Beyond the preview
Go deeper on Transcription factor IIIB 50 kDa subunit (BRF2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Transcription factor IIIB 50 kDa subunit (BRF2).